Fate Therapeutics
12278 Scripps Summit Drive
San Diego
California
92131
United States
Tel: 858.875.1800
Website: http://www.fatetherapeutics.com/
Email: info@fatetherapeutics.com
About Fate Therapeutics
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
174 articles about Fate Therapeutics
-
Fate Therapeutics to Present at Upcoming Investor Conferences in September 2021
9/2/2021
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced that the Company will present at the following upcoming investor conferences.
-
Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma
8/19/2021
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today highlighted positive interim clinical data from the Company’s FT516 and FT596 programs for patients with relapsed / refractory B-cell lymphoma.
-
Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress
8/4/2021
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, reported business highlights and financial results for the second quarter ended June 30, 2021.
-
Fate Therapeutics Appoints Yuan Xu to its Board of Directors
8/4/2021
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced the appointment of Yuan Xu, Ph.D., to its Board of Directors as an independent director.
-
Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy
8/2/2021
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, announced today that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies.
-
Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma
7/16/2021
Fate Therapeutics, Inc. today announced that management will host a virtual event to highlight interim Phase 1 clinical data from its FT596 and FT516 programs for the treatment of relapsed / refractory B-cell lymphomas on August 19, 2021 at 4:30 p.m. ET.
-
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
7/15/2021
Fate Therapeutics, Inc. announced that the Company will host a conference call and live audio webcast on Wednesday, August 4, 2021 at 5:00 p.m. ET to report its second quarter 2021 financial results and provide a corporate update.
-
Shares of Fate climbed nearly 4% in premarket trading after it announced positive interim data from a Phase I study of FT516 for patients with relapsed / refractory B-cell lymphoma.
-
ASH 2020: CRISPR and Vertex's Potential Cure for Sickle Cell Disease and More Glimmers of Hope
12/7/2020
The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5, and there were numerous presentations, abstracts and posters. Here’s a look at some of the stories out of the first day. -
Clinical Catch-Up: July 6-10
7/13/2020
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates. -
Clinical Catch-Up: May 18-22
5/26/2020
Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look. -
Shares of Fate Therapeutics were up more than 21% in premarket trading after the company announced a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer.
-
Clinical Catch-Up: January 13-17
1/20/2020
There were plenty of clinical trial announcements this week. Here's a look. -
Clinical Catch-Up: September 2-8
9/9/2019
Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting. -
Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies
9/19/2018
Option-based Collaboration to Develop Two CAR T-Cell Product Candidates Using Fate’s Proprietary iPSC Product Platform
-
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
-
Fate Therapeutics Announces First Patient Treated In Protmune PROTECT Clinical Trial For The Prevention Of Graft-Versus-Host Disease
1/5/2017
-
Fate Therapeutics To Webcast Conference Call Reporting Third Quarter 2016 Financial Results On November 7, 2016
11/1/2016
-
Fate Therapeutics Announces Issuance Of U.S. Patent Protecting Enhanced Hematopoietic Stem Cell Compositions
10/5/2016
-
Fate Therapeutics Receives FDA Orphan Drug Designation For Protmune In Allogeneic Hematopoietic Cell Transplantation
9/26/2016